eoadjuvant trial on the efficacy of propranolol monotherapy in angiosarcoma (PROPANGIO). - propranolol in angiosarcoma

etherlands Cancer Institute- Antoni van Leeuwenhoek0 个研究点目标入组 14 人开始时间: 2019年10月8日最近更新: 2023年11月13日

适应症

试验速览

暂无简介。

•o Histological proof of angiosarcoma
•o Patients with primary, recurrent and metastasised disease are eligible;
•o Age of 18 years or more;
•o Able and willing to give written informed consent;
•o WHO performance status of 0, 1 or 2;
•o Evaluable disease according to RECIST 1.1 criteria; radiologic visible disease is not obligated in patients with cutaneous angiosarcoma
•o Patients with a window of at least 3 weeks before surgery or systemic therapy;
•o At least one tumor lesion accessible to safely biopsy per clinical judgement of the treating physician.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 14
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 14

•o Contraindication for propranolol therapy,
•o Current treatment with ß-blockade therapy.
•o Any anticancer treatment within 30 days prior to receiving the first dose of investigational treatment; with the exception of hormonal therapy for breast cancer.
•o Concurrent treatment with an anticancer therapy: with the exception of hormonal therapy for breast cancer.

发起方

etherlands Cancer Institute- Antoni van Leeuwenhoek